Epidemiological changes of invasive fungal disease in children with cancer: Prospective study of the National Child Program of Antineoplastic Drugs network, Chile

Abstract

AbstractBackgroundInvasive fungal diseases (IFD) are high morbidity and mortality infections in children with cancer suffering episodes of high‐risk febrile neutropenia (HRFN). IFD epidemiology has changed in the last two decades, with an increasing incidence in recent years due to the growing number of immunocompromised children at risk for IFD. The aim of this study was to evaluate the incidence of IFD in children with cancer in the period 2016–2020 compared to 2004–2006 in six hospitals in Chile.MethodsProspective, multicentre study, carried out between 2016 and 2020 in six hospitals in Chile. The defined cohort corresponds to a dynamic group of HRFN episodes in patients <18 years old with cancer, who at the fourth day of evolution still presented fever and neutropenia (persistent HRFN). Each episode was followed until resolution of FN. The incidence of IFD was calculated between 2016 and 2020 and compared with data obtained in the period 2004–2006. The incidence rate was estimated.ResultsA total of 777 episodes of HRFN were analysed; 257 (33.1%) were considered as persistent‐HRFN occurring in 174 patients. The median age was 7 years (IQR: 3–12 years) and 52.3% (N = 91) were male. Fifty‐three episodes of IFD were detected: 21 proven, 14 probable and 18 possible. Possible IFD were excluded, leaving 239 episodes of persistent‐HRFN with an IFD incidence of 14.6% (95% CI 10.5–19.9) and an incidence rate of 13.6 IFD cases per 1000 days of neutropenia (95% CI 9.5–20.0). Compared to 2004–2006 cohort (incidence: 8.5% (95% CI 5.2–13.5)), a significant increase in incidence of 6.1% (95% CI 0.2–12.1, p = .047) was detected in cohorts between 2016 and 2020.ConclusionWe observed a significant increase in IFD in 2016–2020, compared to 2004–2006 period.